pharma · Peanut allergy · Allergy, Peanut
DBV Technologies
DBV Technologies is a pharma organization headquartered in CHATILLON, FR. Primary therapeutic focus areas include Peanut allergy, Allergy, Peanut. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 pate
Chatillon, FR HQ
220 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Chatillon, FR
- Employees
- 220
- Programs
- 3
- Drugs
- 7
- Patents
- 0
V712-305/EPOPEX
Phase 3 · small molecule · Peanut allergy
V712-305/EPOPEX for Peanut allergy is a Phase 3 program (small_molecule) at DBV Technologies with 1 ClinicalTrials.gov record(s).
Internal code V712-305/EPOPEX
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- DBV Technologies
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Peanut allergy
- Status
- active
- Trials
- 1